

Ochnaflavone, a Naturally Occuring Biflavonoid: Pharmacology and Prospects for Further Research

ABSTRACT

Aims: To profile and address matters surrounding ochnaflavone, derivatives and analogues.

Methodology: Papers concerning ochnaflavone, derivatives and analogues were accessed from search engines such as google scholar and pubmed.

Results: Ochnaflavone and derivatives are compounds bearing ether linkage between the two B-rings of the two flavonoid moieties. These compounds are known to possess potent biological activities such as anti-inflammatory, anti-tumour, anticancer, anti HIV and antimicrobial.

Conclusion: In this paper, an overview summary of ochnaflavone, derivatives and analogues from past to present is given. Thus, the paper provides a sense of focus to researchers; seal breaks the unattended matters, and therefore, spearheads new research areas concerning these compounds.

Keywords: *biflavonoid; ochnaflavone; pharmacokinetics; pharmacology; phytochemistry*

1. INTRODUCTION

A considerable attention has been directed to the use of herbal prescriptions in the form of medicines or supplements in recent years as a compensation of the perceived shortcomings of orthodox medicines [1]. The therapeutic effects of these herbal medicines could be attributed by the presence of phytochemicals also known as secondary plant metabolites. These are naturally occurring compounds in plants specifically designed to protect plants from external hazards. Most of these compounds in synergism or individually have proven to be beneficial to humans in medicinal aspects. Some of the attributes of phytochemicals that has given them approval by many societies include their easy availability and low cost. These compounds may act by causing hormone metabolism modulation, immune system stimulation, antineoplastic or decrease of platelet aggregation effects in the body [2].

Normally these compounds are not the required or essential nutrients to the body to sustain life but their ability to prevent and fight against diseases has been the focus of researches nowadays. Among phytochemicals that have recently attracted attention of scientists worldwide, include flavonoids. This class of compounds are widely distributed among plants, especially in vegetables, fruits and many others. Normally, these compounds are lower molecular weight polyphenolics shown to possess many health benefits to humans [3-5].


Biflavonoids are represented by a small group of flavonoids that may generally be constituted by linking of two identical or non-identical units of flavones, flavanones, isoflavones, flavanols, chalcones, aurones and dihydrochalcones. The two units may be joined in a symmetrical or asymmetrical manner through direct link between carbons of the two units (-C-C-) or through ether bond (-C-O-C-). The linkage between ring A of one flavonoid to ring B of another (AB biflavonoids) is the most commonly observed. Others constitute the linkage between the two ring A (AA biflavonoids) or between the two C rings (3,3''-CC biflavonoids). The most rarely observed biflavonoids from nature are the ones with linkage between the two B rings (BB biflavonoids) [6].

The journey towards biflavonoids isolation began when ginkgetin was isolated from the leaves of maidenhair tree (*Ginkgo biloba* L.) by Furukawa in 1929, however, to date, the numbers and diversity of biflavonoids keep on increasing. This is due to the structural diversity arising from differences in the position and nature of interflavonoid linkage regardless of the substitution pattern. The diversity among biflavonoids increases further with the presence and type of the substituent/ functional groups and stereogenic centers in their skeleton. So far, about 200 biflavonoids have been isolated from different Gymnosperm and Angiosperm species. Few families such as Anacardiaceae,

Berberidaceae, Burseraceae, Caprifoliaceae, Casuarinaceae, Euphorbiaceae, Guttiferae (especially Garcinia), Haemodoridae, Iridaceae, Labiatae, Leguminosae, Loganiaceae, Ochnaceae, Piperaceae, Rhamnaceae, Rutaceae, Salicaceae, Thymelaeaceae and Velloziaceae have been reported to be sources of biflavonoids. This is a clear indication that the pathway to which biflavonoids are biosynthesized is more specialized and take place only in some few angiospermous families, thus, making these compounds of chemotaxonomic importance in some plant families such as Taxaceae and Iridaceae to Ginkgoaceae and Ochnaceae [7,8].

Biflavonoids have become the centre of attention to researchers these days, due to their ability to demonstrate diverse interesting biological activities caused by their structural variation. These compounds have shown an array of pharmacological properties including antioxidant, antiproliferative, or anti-inflammatory, indicating their potentiality in pharmacological industry [9-11].

The biologically active ochnaflavone (**1**) and derivatives are BB' biflavonoids that may either constitute flavone-flavone, flavone-flavanone or flavanone-flavanone units that are linked in C-O-C manner. The first isolation of compound **1** was reported from *Ochna squarrosa* Linn. (Ochnaceae) in 1973 by Okigawa and group [12]. The compound and/or derivatives have since then been isolated from many other plant species especially those belonging to the family Ochnaceae, genus *Ochna* [13].



1

2. SOURCES

2.1 Natural Sources









So far, plants are the only natural sources of compound **1** and its derivatives, the following paragraphs describe the structures of the derivatives and their sources. The plant families such as Ochnaceae, Caprifoliaceae, Paracryphiaceae (Quintiniaceae), Grossulariaceae and Selaginellaceae (club mosses or spike mosses) have been identified to be the sources of these compounds.

The isolation of ochnaflavone (**1**) has been reported from various plant species such as *Lonicera japonica* Thunb. (Leaves) [14], *Cespedesia macrophylla* Seem. (Leaves), *Cespedesia spathulata* (Ruiz & Pav.) Planch. (Leaves) [15], *Luxemburgia nobilis* Eichl. (Aerial parts) [16, 17], *Ochna beddomei* Gamble. (Leaves and stem bark) [15], *Ochna integerrima* (Lour) Merr. (leaves) [18], *Ochna lanceolata* Spreng. (Stem bark) [19], *Ochna obtusata* DC (Leaves) [15, 20], *Ouratea staudtii* Van Tiegh. Ex Keay. (Aerial parts) [21].

Derivatives of compound **1**, among others, 7-O-methylochnaflavone (**3**) is obtained from the leaves of both *Lonicera japonica* Thunb. and *Ochna integerrima* (Lour) Merr. [22]. From the leaves of both *Cespedesia macrophylla* Seem. and *Cespedesia spathulata* (Ruiz & Pav.) Planch., 7"-O-methylochnaflavone (**4**) have been isolated [15]. 2'-hydroxy-4'-O-methyl derivative, triclisinone (**5**) has been reported from aerial parts of *Triclisia gillettii* [23].

The dihydro derivatives of compound **1**, such as 2",3"-Dihydroochnaflavone (**6**) have been obtained from leaves of *Luxemburgia nobilis* Eichl. and aerial parts of *Luxemburgia octandra* St. Hil. [17]. The isolation of the methoxy derivative of dihydroochnaflavones, viz 7"-O-methyl-2",3"-dihydroochnaflavone (**7**), has been reported from the leaves of *Ochna integerrima* (Lour) Merr. [24]. 2,3-dihydroochnaflavone (**8**) was reported from leaves and stem bark of *Ochna beddomei* Gamble.

[15, 25], stem bark of *Ochna lanceolata* Spreng. [19], leaves of *Ochna obtusata* DC. [20], *Selaginella labordei* Hieron. ex Christ. (Aerial parts) [26], *Luxemburgia nobilis* (Leaves) [16]. Isolation of 7-O-methyl- derivative of 2,3-dihydroochnaflavone (**9**) from leaves of *Ochna beddomei* Gamble. [15], *Ochna obtusata* DC. [20] has been reported. The stem bark of *Ochna beddomei* Gamble. yielded 7,4',7"-tri-O-methyl-2,3-dihydroochnaflavone (**10**) [15, 25]. From aerial parts of *Selaginella labordei* Hieron. ex Christ. the isolation of 6,6"-dimethyl-2,3-dihydroochnaflavone (**11**) has been reported [26]. 7-O-methyl- derivative of tetrahydroochnaflavone (**12**) was isolated from leaves of both *Ochna beddomei* Gamble. and *Quintinia acutifolia* Kirk [15]. From the leaves of the latter, 7,7"-di-O-methyl-2,3,2",3"-tetrahydroochnaflavone (**13**) and 2,3,2",3"-Tetrahydroochnaflavone (**14**) have been reported [27]. Flavanol-flavanol derivative, the 5,7,4',5",7"-pentahydroxy-biflavanonol derivative, was reported from *Hypnum cupressiforme* Hedw. [28, 29].




All of the isolated derivatives so far are of -O-methyl- nature with an exception of 6,6"-dimethyl-2,3-dihydroochnaflavone (**11**). The prenylated, pyranyl and other substituents (with exception of methoxy or methyl derivatives) of compound **1** have neither been synthesized nor isolated, implying more biological activities to be unveiled (anticipated). From this, it can be concluded that, although compound **1** and derivatives have shown very impressive biological activities (to be discussed in the following sections), less is known concerning the derivatives that are not yet isolated/synthesized, thus, their pharmacological profiles remain masked.

2.2 Synthetic sources


Since isolation from natural sources is not the only means to obtain phytochemicals, different synthetic methods have been developed as an alternative source. Since these compounds are available in small amounts from their natural sources, synthesis will ensure QSAR (Quantitative Structure-Activity Relationship) studies, thus, revealing their pharmacological capabilities.

As it is, compound **1** is comprised of -C-O-C- between its two flavone moieties, strategically its synthesis may be carried out through Baker-Venkatarman rearrangement of the corresponding diphenyl ether dialdehyde, followed by flavone nuclei building [12] as illustrated in **Scheme 1**.




Scheme 1: Synthesis of *penta-O*-methoxychnaflavone [12]

Another approach would be building up of the diaryl ether bridge by a simple nucleophilic aromatic substitution reaction, followed by diflavonyl nuclei building as illustrated in **Scheme 2** [30].



Scheme 2: Synthesis of ochnaflavone and *Penta-O*-methyl-2,3,2'',3''-tetrahydroochnaflavone [30]


Yet another approach was first building up of the flavone nuclei then through Ullman coupling diaryl ether linkage was achieved as illustrated in **Scheme 3** [31].



Scheme 3: Synthesis of Ochnaflavone [31]


Synthesis of derivatives of compound **1** focused on the dihydro and/or methoxy substituents, thus, synthesis of 2,3,2'',3''-tetrahydroochnaflavone and its methoxy derivative was reported by Yingpeng et al (2015), and Ndoile and van-Heerden 2013 respectively [30, 32].

128 Analogs of compound **1** that are composed of -C-S-C- and -C-NH-C- interflavonoid linkage have been
 129 reported [33]. Stepwise building up of the target biflavone molecules is as illustrated in **schemes 4**
 130 and **5** for -C-NH-C- and -C-S-C- analogs respectively.



131

132 **Scheme 4:** Synthesis of -C-NH-C- Analog of Ochnaflavone [33]



133

134 **Scheme 5:** Stepwise Synthesis of -C-S-C- Analog of Ochnaflavone [33]

135 It should be noted that, concerning structural activity relationship studies, substituents like benzoyls,
 136 prenyls, pyranlys and others have not been synthesized, thus, their pharmacological effects not
 137 known/established.

138 3. PHARMACOLOGY

139 The advancement of pharmacology has provided more evidence through laboratory testing on the
 140 inhibitory nature of compound **1**. Compound **1** inhibits rat platelet phospholipase A₂ (PLA₂), rat
 141 peritoneal macrophage arachidonate release and proliferation of lymphocyte [34]. Moreover, the
 142 compounds regulated ERK and MMP-9 proteins thus inhibiting proliferation of smooth muscle cells
 143 [35, 36]. Furthermore, they blocked phosphatidylethanolamine (PE) degradation in rat liver microsome
 144 induced with CCl₄ [37]. Lastly but not the least, the compounds strongly inhibited degranulation
 145 reaction, thus, providing a basis for novel anti-inflammatory drugs design and development. The
 146 mechanism through which these compounds exhibit these inhibitory activities are but not limited to

affecting NF- κ B and ERK pathways, down regulation of inducible nitric oxide, arachidonate 5-lipoxygenase and cyclooxygenase (COX)-2 [35, 36].

Thus far, a wide range of pharmacological activities have been demonstrated by ochnaflavone and derivatives, thereby attracting an increased attention from researchers of different fields. This paper is aimed at profiling the sources, derivatives and analysis on recent progress in pharmacological properties of ochnaflavone and its derivatives, thus, point out future perspectives and issues surrounding these compounds, therefore provide stimulant for further research.

As in ochnaflavone, most pharmacologically relevant natural product molecules are composed of diaryl ether group. This structural feature is part of various significant pharmaceuticals with antibiotic activities, such as vancomycin, teicoplanin, the antiviral peptide K-13 and the antitumoral bouvardin. Ochnaflavone, its derivatives and analogs have demonstrated impressive biological activities including anti-inflammatory, anticancer and anti-HIV, as described in the following paragraphs.

3.1 Anti-inflammatory, anti-tumour and anticancer activity

Researches in anti-inflammatory and anti-tumor activities are ongoing, new ideas are developed due to advancement in technology. Based on early researches, biflavonoids appear to utilize variety of mechanisms to manifest the observed biological activity. For instance, compound **1** and derivatives have expressed their ability to suppress the activity of proinflammatory enzymes such as cyclooxygenase-2 and lipoxygenase-5 in reducing inflammation. These compounds inhibited cyclooxygenase-2 (COX-2) in BMMC (Bone Marrow-Derived Mast Cells) at $IC_{50} = 0.6 \mu M$, additionally, they also inhibited leukotriene C4 production (LTC4) at $IC_{50} = 6.5 \mu M$, indicating dual inhibitory activity (cyclooxygenase-2/5-lipoxygenase). Moreover, the compounds suppressed degranulation reaction at $IC_{50} = 3.0 \mu M$ [38].

Ochnaflavones have been known to suppress hypertrophy and proliferation in smooth muscle cells. The effect of the compounds on HASMC (human aortic smooth muscle cells) has been investigated by Suh et al 2006. It is well understood that the occurrence of atheromas on the walls of arteries (atherogenesis) may be caused by infection on vascular smooth muscle cells (VSMC). Therefore, any antiproliferatory molecule will be able to treat the condition. The ability of these compounds to exert anti-atherogenic activity has been correlated to the inhibition of proliferation of VSMC through down regulation of metalloproteinase-9 (MMP-9) [35]. However, this is not the only mechanism through which these compounds show their anti-inflammatory activities. Others include inhibition of LPS-induced iNOS expression. Total inhibition of lipopolysaccharide (LPS)-induced iNOS expression in mouse macrophage cells at $IC_{50} = 5.46 M$ was observed. These compounds exhibited the reported activity by blocking the inhibition of NF- κ B transcription factor binding activities [36]. Another mechanism includes cell cycle arrest and apoptosis induction; evidenced by DNA fragmentation induction, caspase-3, -8 and -9 activation, and ADP-ribose polymerase cleavage. The growth inhibitory activity of these compounds on cultured human colorectal cancer cells (HCT-15) was inhibited at $IC_{50} = 4.1 \mu M$ [39].

An irreversible inhibition of lymphocyte proliferation was observed when ochnaflavone was treated on lymphocytes proliferation induced by both Con A and LPS. The activity of ochnaflavone has been demonstrated to be superior compared to that of apigenin and quercetin. Thus, the inhibitory effects of ochnaflavone persisted even after washing of the cells but the proliferation activity was restored after washing in the case of apigenin and quercetin treated cells. The suppression activity of ochnaflavone persisted up to 48 hours after incubation, while that of apigenin was gradually diminishing time dependently. Quercetin and apigenin could only inhibit both Con A- and LPS induced lymphocyte proliferation while ochnaflavone on the other hand inhibited the proliferation on both cells irreversibly [40].

Among various inflammatory mediators secreted upon activation of macrophages is arachidonic acid (AA) which depending on location, species and stimulant is converted to eicosanoids with pro-inflammation properties like PGE2, LTC4 and 5-HETE. Thus, the inhibition of AA secretion from activated macrophages is considered as a key point in anti-inflammatory potential of a given compound. In a study by Lee et al (1997), ochnaflavone inhibited AA release in PMA-induced cells at $IC_{30} = 1.5 \mu M$ and in A 23187-induced cells at $IC_{30} = 8.3 \mu M$. Apigenin which is a monomer of compound **1**, did not show any significant inhibition. Generally, it was discovered that ochnaflavone

200 inhibits AA release by blocking PLA2 pathway [35]. Inhibitory effects of ochnaflavone on COX-2
201 catalysed production of PGE2 from LPS-activated RAW 264.7 cells was observed at IC₅₀ value of
202 1.08 µM [31]. Inhibition of phospholipase A2 (PLA2-IIA) would result into inflammation reduction, thus,
203 ochnaflavone showed to be stronger seven fold than amentoflavone [31].

204 Ochnaflavone derivatives exhibited potent growth inhibition on leukemia cells, 2,3,2",3"-
205 tetrahydroochnaflavone, 2",3"-dihydroochnaflavone and 7,7"-Di-O-methyl-2,3,2",3"-
206 tetrahydroochnaflavone actively inhibited the growth of lymphocytic leukemia cells (P388) with IC₅₀ =
207 8.2, 3.1, 8.7 µg/mL, respectively [27, 41].

208 The effect of ochnaflavone on the fungal arthritis was determined by examining T cell
209 immunoregulation. The compound inhibited the growth of the mice footpad edema at the peak of
210 septic state by 45% at 2 mg dose. The observed inhibition was attributed by T helper 1 cytokines
211 suppression (causing Th2 dominance). There is a relationship between arthritis severity and
212 macrophages (which produce NO and thus aggravating joint disease) activation and abundance. The
213 compound exhibited these activities by reducing the population of these macrophages, for instance, at
214 40 µg/mL of the compound, the population of macrophage was reduced by 70% [42].

215 The protective effects of ochnaflavone was analysed by pre-treating rat liver microsomes with the
216 compound at 2-16 µM. Upon CCl₄-induced acute liver injury, the marked reduction in the levels of
217 degradation phosphatidylethanolamine (PE) was observed. Furthermore, the compound exhibited
218 inhibition on rat platelet sPLA at IC₅₀ = 3.45 µM and lipid peroxidation at IC₅₀ = 7.16 µM [37].

219 2",3"-dihydroochnaflavone, a flavone-flavanone biflavonoid showed cytotoxicity at IC₅₀ = 17.2 µM
220 against murine Ehrlich carcinoma and IC₅₀ = 89.0 µM against human leukemia K562 cells.
221 Furthermore, the acetyl and methyl derivatives of 2",3"-dihydroochnaflavone exhibited low cytotoxicity
222 against the same cells. Moreover, 2",3"-dihydroochnaflavone and its acetyl derivative showed to be
223 inhibitors of DNA topoisomerases I and II – α in the relaxation and decatenation assays. 2",3"-
224 dihydroochnaflavone in a test with topoisomerase I, showed to be a DNA interacting agent, that is, it
225 may cause unwinding of the DNA, upon spectrophotometric titration, a pronounced hypochromic
226 effect was observed [17].

227 The imbalance between the inflow, neutralization and the outflow of Reactive Oxygen Species (ROS)
228 may result into oxidative stresses, leading into various pathologies, but, under extreme conditions cell
229 death may occur. Generally, biflavonoids have shown such robust neuroprotection against ROS-
230 induced stress. Evaluation of the neuroprotective effects of ochnaflavone showed strong
231 neuroprotection activity against cytotoxic insults induced by oxidative stress and amyloid β. These
232 results, however, suggests the therapeutic potential of the compound against ischemic stroke and
233 Alzheimer's disease (neurodegenerative diseases). It was further shown that the compound have no
234 antioxidative effects, thereby, indicating that the observed neuroprotection might be through blockage
235 of cell death cascades. Inhibiting cell death cascades was effected by blocking staurosporine (known
236 to mediate apoptosis) induced cytotoxic stress (at 10 µM). However, the compound showed minimal
237 effects at 0.4–10 µM on the etoposide-induced cell death [14].

238 The -C-NH-C- and -C-S-C- analogs of ochnaflavone have been synthesized, their inhibitory effects on
239 cyclooxygenase-2 (COX-2) mediated prostaglandin E2 production was observed to be weaker
240 than that of ochnaflavone. However, strong inhibitory effects on nitric oxide production on
241 lipopolysaccharide (LPS)-treated RAW 264.7 cells was observed [33]. As far as pharmacological
242 properties of analogs is concerned, a wide range of bioactivities accompanied by their mechanisms
243 need to be established/investigated.

244 3.2 Other biological activities

245 Basing on HIV-1 RT and cell assays, 7"-O-methylochnaflavone and 7"-O-methyl-2",3"-
246 dihydroochnaflavone were evaluated for their anti HIV activity. The compounds exhibited EC₅₀ of 2.0
247 and 0.9 mg/mL in the syncytium assay respectively, while in the HIV-1 RT assay, IC₅₀ 2.0 and 2.4
248 mg/mL were observed, respectively. The observed activities for both compounds were higher than
249 that of vitexin, a non-nucleoside RT standard inhibitor. 2,3, 2",3"-tetrahydroochnaflavone exhibited
250 significant cytotoxicity effects against human nasopharynx carcinoma cells (KB) [22, 43].

Antibacterial activity of ochnaflavone and 7-O-methylochnaflavone against *Escherichia coli*, *Pseudomonas aeruginosa*, *Enterococcus faecalis* and *Staphylococcus aureus* indicated gram-negative are more susceptible to chemical attack than gram-positive. Thus, the former showed to be more susceptible to ochnaflavone than the latter with MIC = 31.3 µg/mL (*P. aeruginosa*) and 62.5 µg/mL (*S. aureus*) [44]. Significant antitubercular activity was displayed by triclisinone a 2'-hydroxy-4'-methoxyochnaflavone (**5**) at MIC = 62.5 µg/mL against *Mycobacterium tuberculosis* [23].

Despite the impressive biological activities demonstrated by ochnaflavone, derivatives and analogs, the absorption and distribution properties of these compounds in animals are not yet known. Other biflavonoids investigated include amentoflavone and ginkgetin as analgesics, where potent activity was observed upon intraperitoneal (i.p.) injection and not through oral administration [45]. Similarly, by i.p. injection, antinociceptive activity of 3-8" binaringenin was observed [46]. Through i.p. injection, anti-inflammatory activity of amentoflavone by revealed to be ½ - ⅓ of that of the standard drug indomethacin [9]. Arthritic inflammation in rats was reduced following i.p. injection at 5-20 mg/kg/day of ginkgetin [47]. Generally, there has been a reduction of/no activity on oral administration of these compounds, implying **low oral bioavailability** of these compounds, thus, same studies could be done with ochnaflavone, its derivatives and analogs.

4. PHARMACOKINETICS

Despite of the impressive biological activities of the ochnaflavone, its analogs and derivatives, the pharmacokinetic studies have not yet been done, therefore, this review, serves as an eye opener to researchers on this very important area of research.

5. CONCLUSION

It can be reasonably concluded from the information cited above that ochnaflavone, its derivatives and analogs possess a variety of pharmacological activities, including but not restricted to anti-inflammation, anti-tumor, antimicrobial activities, and also have effects on the central nervous and cardiovascular systems. These impressive pharmacological properties displayed by these compounds are expressed through modulation of various enzymes/proteins with key functions in the cells.

5.1 New Research Avenues

Pharmacokinetics of ochnaflavone and derivatives are not yet known, the effects of structural modifications, synthesis of precursors and introduction of pharmaceutical additives to enhance their bioactivity/bioavailability are recommended.

Although ochnaflavone and derivatives have been isolated and identified from many plants belonging to different families, the recovery and the reproduction of these plants is very costly in cases of demand for large amounts of samples, therefore, a solution to address this challenge is highly needed. Some of the solutions might be through biological synthesis (which has not been done) and chemical synthesis, allowing formulations preparation, structural modification, Absorption-Distribution-Metabolism-Excretion (ADME), and toxicological studies to be carried out.

Concerning derivatives of ochnaflavone that have not yet been isolated and identified from nature, synthesis could be employed so as to better study these compounds. Moreover, incorporation of nanomaterials to improve their surface and enhance solubility is suggested to create new pharmacological applications.

6. REFERENCES

1. Arika WM, Abdirahman YA, Mawia MA, Wambua KF, Nyamai DW. *In Vivo* Antidiabetic Activity of the Aqueous Leaf Extract of *Croton macrostachyus* in Alloxan Induced Diabetic Mice. *Pharm Anal Acta*. 2015;6:447.
2. Andre CM, Larondelle Y, Evers D. Dietary antioxidants and oxidative stress from a human and plant perspective: a review. *Current Nutrition & Food Science*. 2010;6(1): 2-12.

- 297 3. Vauzour D, Rodriguez-Mateos A, Corona G, Oruna-Concha MJ, Spencer JP. Polyphenols and
298 human health: prevention of disease and mechanisms of action. *Nutrients*. 2010;2:1106–31.
- 299 4. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. *Sci World J*.
300 2013;2013:62750.
- 301 5. Reis JF, Monteiro VV, De Souza Gomes R, Do Carmo MM, Da Costa GV, Ribera PC, et al. Action
302 mechanism and cardiovascular effect of anthocyanins: a systematic review of animal and human
303 studies. *J Transl Med*. 2016;14:315.
- 304 6. Ferreira D, Slade D, Marais, JPJ. *Bi-, tri-, tetra-, penta-, and hexaflavonoids*. In M. Andersen and K.
305 R. Markham, (Eds.): *Flavonoids: chemistry, biochemistry and applications*, pp. 1101-1128. CRC
306 Press, Taylor & Francis Group, Boca Raton, FL. 2006.
- 307 7. Sagrera G, Bertucci A, Vazquez A, Seoane G. Synthesis and antifungal activities of natural and
308 synthetic biflavonoids. *J Med Chem*. 2011;19:3060-3073.
- 309 8. Geiser H, Quinn C. Biflavonoids. In: HARBONE, J. B.; MABRY, T. J. *The Flavonoids*. London:
310 Chapman and Hall. 1998.
- 311 9. Kim HP, Park H, Son KH, Chang HW, Kang SS. Biochemical pharmacology of biflavonoids:
312 Implications for anti-inflammatory action. *Arch Pharm Res*. 2008;31:265-273.
- 313 10. Yu S, Yan H, Zhang L, Shan M, Chen P, Ding A et al. A review on the phytochemistry,
314 pharmacology, and pharmacokinetics of amentoflavone, a naturally-occurring biflavonoid.
315 *Molecules*. 2017;22(2):299.
- 316 11. Gontijo VS, Dos Santos MH, Viegas CJr. Biological and chemical aspects of natural biflavonoids
317 from plants: a brief review. *Mini Rev Med Chem*. 2017;17:834–62.
- 318 12. 30. Okigawa M, Kawano N, Aqil M, Rahman W. Ochnaflavone and its derivatives: a new series of
319 diflavonyl ethers from *Ochna squarrosa* Linn. *J Chem Soc, Perkin I*. 1976;580-583.
- 320 13. Ismail AM, Musa AM, Nasir T, Magaji MG, Jega YA, Ibrahim I. Anti-proliferative study and isolation
321 of Ochnaflavone from the ethyl acetate-soluble fraction of *Ochna kibbiensis* Hutch & Dalziel. *Nat*
322 *Prod Res*. 2016;1:1-4.
- 323 14. Kang SS, Lee JY, Choi YK, Song SS, Kim JS, Jeon SJ, Han YN, Son KH, Han BH.
324 Neuroprotective effects of naturally occurring biflavonoids. *Bioorg Med Chem Lett*. 2005;15:3588-
325 3591.
- 326 15. Chen J, Chang HW, Kim HP, Park H. Synthesis of phospholipase A2 inhibitory biflavonoids.
327 *Bioorg Med Chem Lett*. 2006;16:2373-2375.
- 328 16. Likhitwitayawuid K, Rungserichai R, Ruangrunsi N, Phadungcharoen T. Flavonoids from *Ochna*
329 *integerrima*, *Phytochem*. 2001;56:353-357.
- 330 17. de Oliveira MCC, de Carvalho MG, Grynberg NF, Brioso PS. A biflavonoid from *Luxemburgia*
331 *nobilis* as inhibitor of DNA topoisomerases. *Planta Med*. 2005;71:561-563.
- 332 18. Likhitwitayawuid K, Kaewamatawong R, Ruangrunsi N. Mono- and biflavonoids of *Ochna*
333 *integerrima*. *Biochem Syst Ecol*. 2005;33:527-536.
- 334 19. Reddy BAK, Reddy NP, Gunasekar D, Blond A, Bodo B. Biflavonoids from *Ochna lanceolata*,
335 *Phytochem Lett*. 2008;1:27-30.
- 336 20. Rao KV, Sreeramulu K, Venkata Rao C, Gunasekar D, Martin MT, Bodo B. Two new biflavonoids
337 from *Ochna obtusata*, *J Nat Prod*. 1997;60:632-634.

- 338 21. à Zintchem AA, Atchadé AdT, Tih RG, Mbafor JT, Blond A, Pegnyemb DE, et al. Flavonoids from
339 *Ouratea staudtii* Van Tiegh. (ex Keay) (Ochnaceae). Biochem Syst Ecol. 2007;35:255-256.
- 340 22. Reutrakul V, Ningnuek N, Pohmakotr M, Yoosook C, Napaswad C, Kasisit J, Santisuk T,
341 Tuchinda P. Anti HIV-1 flavonoid glycosides from *Ochna integerrima*. Planta Med. 2007;73:683-
342 688.
- 343 23. Tiam ER, Bikobo DSN, Zintchem AAA, Nyemeck II N M, Ndedi E Del FM, Diboué PHB, et al.
344 Secondary metabolites from *Triclisia gilletii* (De Wild) Staner (Menispermaceae) with
345 antimycobacterial activity against *Mycobacterium tuberculosis*. Nat Prod Res.2017.
- 346 24. Kaewamatawong R, Likhitwitayawuid K, Ruangrunsi N, Takayama H, Kitajima M, Aimi N. Novel
347 biflavonoids from the stem bark of *Ochna integerrima*. J Nat Prod. 2002;65:1027-1029.
- 348 25. Jayakrishna G, Reddy MK, Jayaprakasam B, Gunasekar D, Blond A, Bodo B. A new biflavonoid
349 from *Ochna beddomei*. J. Asian Nat Prod Res. 2003;5:83-87.
- 350 26. Xu JC, Liu XQ, Chen KL. A new biflavonoid from *Selaginella labordei* Hieron. ex Christ. Chinese
351 Chem Lett. 2009;20:939-941.
- 352 27. Ariyasena J, Baek SH, Perry NB, Weavers RT. Ether-linked biflavonoids from *Quintinia acutifolia*.
353 J Nat Prod. 2004;67:693-696.
- 354 28. Sievers H, Burkhardt G, Becker H, Zinsmeister HD. Hypnogenols and other dihydroflavonols from
355 the moss *Hypnum cupressiforme*. Phytochem. 1992;31:3233-3237.
- 356 29. Sievers H, Burkhardt G, Becker H, Zinsmeister HD. Further biflavonoids and 3'-phenylflavonoids
357 from *Hypnum cupressiforme*. Phytochem. 1994;35:795-798.
- 358 30. Ndoile MM, van-Heerden F. Total synthesis of ochnaflavone. Beilstein J Org Chem. 2013;9:1346-
359 1351.
- 360 31. Kim SS, Vo VA, Park H. Synthesis of Ochnaflavone and Its Inhibitory Activity on PGE2
361 Production. Bull Korean Chem Soc. 2014;35:3219-3223.
- 362 32. Yingpeng Z, Sensen L, Aihong S, Yunshang Y, Wei T. First Total Synthesis of (±)-2,3,2",3"-
363 Tetrahydroochnaflavone. Chin J Org Chem. 2015;35:2114-2118.
- 364 33. Pham TA, Han C, Park H. Synthesis of Ochnaflavone Analogs and Their Inhibitory Activity on
365 PGE2 and NO Production Against LPS-treated RAW 264.7 Cells. Bull Korean Chem Soc.
366 2017;1229-5949.
- 367 34. Lee SJ, Son KH, Chang HW, Kang SS, Kim HP. Inhibition of arachidonate release from rat
368 peritoneal macrophage by biflavonoids. Arch Pharm Res. 1997;20:533-538.
- 369 35. Suh SJ, Jin UH, Kim SH, Chang HW, Son JK, Ho Lee S, Son KH, Kim CH. Ochnaflavone inhibits
370 TNF-α-induced human VSMC proliferation via regulation of cell cycle, ERK1/2, and MMP-9. J Cell
371 Biochem. 2006;99:1298-1307.
- 372 36. Suh SJ, Chung TW, Son MJ, Kim SH, Moon TC, Son KH, Kim HP, Chang HW Kim CH. The
373 naturally occurring biflavonoid, ochnaflavone, inhibits LPS-induced iNOS expression, which is
374 mediated by ERK1/2 via NF-kB regulation, in RAW264.7 cells. Arch Biochem Biophys.
375 2006;447:136–146.
- 376 37. Moon TC, Hwang HS, Quan Z, Son KH, Kim CH, Kim HP, Kang SS, Son JK, Chang HW.
377 Ochnaflavone, Naturally Occurring Biflavonoid, Inhibits Phospholipase A2 Dependent
378 Phosphatidylethanolamine Degradation in a CCl₄-Induced Rat Liver Microsome. Biol Pharm Bull.
379 2006;29:2359-2361.

- 380 38. Son MJ, Moon TC, Lee EK, Son KH, Kim, H. P., Kang SS, Son JK, Leet SH, Chang HW. Naturally
381 Occurring Biflavonoid, Ochanflavone, Inhibits Cyclooxygenases-2 and 5-Lipoxygenase in Mouse
382 Bone Marrow derived Mast Cells. Arch Pharm Res. 2006;29:282-286.
- 383 39. Kang YJ, Min HY, Hong JY., Kim YS, Kang SS, Lee SK. Ochnaflavone, a Natural Biflavonoid,
384 Induces Cell Cycle Arrest and Apoptosis in HCT-15 Human Colon Cancer Cells. Biomol Ther.
385 2009;17:282-287.
- 386 40. Lee SJ, Choi JH, Son KH, Chang HW, Kang SS, Kim HP. Suppression of mouse lymphocyte
387 proliferation *In vitro* by naturally-occurring biflavonoids. Life Sciences. 1995;57:551-558.
- 388 41. Lee JS, Choi HJ, Kim MJ, Park JS. *In vitro* Anti-Cancer Effect of Wellness-Compound
389 (Ochnaflavone). J Digit Converg. 2015;13:337-344.
- 390 42. Lee JH. Involvement of T-cell Immunoregulation by Ochnaflavone in Therapeutic Effect on Fungal
391 Arthritis due to *Candida albicans*. Arch Pharm Res. 2011;34:1209-1217.
- 392 43. Gunasekar D, Jayaprakasam B, Damu AG. Polyphenol Commun.: XIXth International Conference
393 on Polyphenols, p. 175, Lille (France). 1998.
- 394 44. Makhafole TJ, Samuel BB, Elgorashi EE, Eloff JN. Ochnaflavone and Ochnaflavone 7-O-methyl
395 Ether two Antibacterial Biflavonoids from *Ochna pretoriensis* (Ochnaceae). Nat Prod Commun.
396 2012;7:1601-1604.
- 397 45. Lim H, Son KH, Chang HW, Kang SS, Kim HP. Effect of anti-inflammatory biflavonoid, ginkgetin,
398 on chronic skin inflammation. Biol Pharm Bull. 2006;29:1046-1049.
- 399 46. Bittar M, de Souza MM, Yunes RA, Lento R, Monache FD, Filho VC. Antinociceptive activity of
400 I3,I18- binaringenin, a biflavonoid present in plants of Guttiferae. Planta Med. 2000;66:84-86.
- 401 47. Kim HK, Son KH, Chang HW, Kang SS, Kim HP. Inhibition of rat adjuvant-induced arthritis by
402 ginkgetin, a plant biflavone from *Ginkgo biloba* leaves. Planta Med. 1999;65:465-467.